1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US

BACKGROUND: Sotrovimab, a monoclonal antibody (mAb), received Emergency Use Authorization (EUA) for the treatment of high-risk outpatients with symptomatic COVID-19. The study objective was to evaluate real-world effectiveness of sotrovimab (500 mg intravenous) in reducing the risk of mortality or h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Mindy M, Gibbons, Daniel C, Birch, Helen, Patel, Vishal, Bell, Christopher F, Drysdale, Myriam, Satram, Sacha, Reyes, Carolina M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752579/
http://dx.doi.org/10.1093/ofid/ofac492.983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752579/
http://dx.doi.org/10.1093/ofid/ofac492.983

Ejemplares similares